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Abstract
Paclitaxel (Brand name Taxol) is widely used in the treatment of common cancers 
like breast, ovarian and lung cancer. Although highly effective in blocking 
tumor progression, paclitaxel also causes peripheral neuropathy as a side effect in 
60-70% of chemotherapy patients. Recent efforts by numerous labs have aimed at 
defining the underlying mechanisms of paclitaxel-induced peripheral neuropathy 
(PIPN). In vitro models using rodent dorsal root ganglion neurons, human 
induced pluripotent stem cells, and rodent in vivo models have revealed a 
number of molecular pathways affected by paclitaxel within axons of sensory 
neurons and within other cell types, such as the immune system and peripheral 
glia, as well skin. These studies revealed that paclitaxel induces altered calcium 
signaling, neuropeptide and growth factor release, mitochondrial damage and 
reactive oxygen species formation, and can activate ion channels that mediate 
responses to extracellular cues. Recent studies also suggest a role for the matrix-
metalloproteinase 13 (MMP-13) in mediating neuropathy. These diverse changes 
may be secondary to paclitaxel-induced microtubule transport impairment. 
Human genetic studies, although still limited, also highlight the involvement of 
cytoskeletal changes in PIPN. Newly identified molecular targets resulting from these 
studies could provide the basis for the development of therapies with which to 




The taxanes are microtubule stabilizing agents that provide great benefits in treating a 
large number of cancers, including breast, ovarian and lung cancers. Therefore, a large 
cohort of cancer patients is treated with paclitaxel or other taxanes each year.  
Unfortunately, neuropathy is a major and dose-limiting side effect of treatment with 
taxanes. It has been estimated that over half the patients treated with the most 
commonly used taxane, paclitaxel, experience symptoms; and a subset develop long-
lasting, irreversible peripheral neuropathy due to the treatment (Nyrop et al., 2019). The 
symptoms of neuropathy include pain, tingling, cold-sensitivity and numbness that 
typically presents in a stocking glove distribution. Many patients experience allodynia, 
so that normal stimuli such as light touch are experienced as severe pain. As these 
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symptoms dramatically interfere with quality of life (Miaskowski et al., 2018), multiple 
recent studies have focused on understanding the mechanisms for paclitaxel-induced 
peripheral neuropathy and how this condition can be prevented or treated (Flatters et 
al., 2017; Fukuda et al., 2017).  
Diverse approaches have been taken to investigate paclitaxel-induced peripheral 
neuropathy, including in vitro studies investigating the direct effects of paclitaxel on 
rodent peripheral sensory neurons of the dorsal root ganglia (DRG) and DRGs derived 
from human induced pluripotent stem cells, in vivo studies using rodent models, and 
genetic approaches in humans (Fukuda et al., 2017; Gornstein and Schwarz, 2014; 
Smith et al., 2016). These have highlighted several features of the disorder. The initial 
effects of paclitaxel appear to reflect on-target changes in the axonal microtubules of 
sensory neurons. Subsequent changes have been found in intracellular Ca++ regulation, 
axonal transport, mitochondrial function, and neuropeptide secretion (Bobylev et al., 
2015; Chiba et al., 2016) (Li et al., 2019; Li et al., 2018; Pease-Raissi et al., 2017). 
Interactions within the peripheral nervous system among these neurons and 
surrounding Schwann cells, satellite glial cells, immune cells and specialized 
intradermal mechanoreceptor cells, such as Merkel cells, epidermal keratinocytes, as 
well as the interactions of the central axon of DRG sensory neurons with astrocytes and 
microglia may all contribute to the progression of the disease (Sekiguchi et al., 2018; 
Zhang et al., 2008). The complex interplay of all of these processes is also affected by 
genetic predisposition of the individual patients.  
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Here we review recent studies using diverse approaches to understand the 
pathogenesis of paclitaxel-induced peripheral neuropathy (PIPN) (Figure 1). To date, 
none of these approaches have yielded new clinical methods for preventing or treating 
this debilitating consequence of chemotherapy. However, integration of these multiple 
approaches will ultimately yield insights regarding the mechanisms that contribute to 
this neuropathy, and so will provide new techniques for preventing or treating this 
devastating, iatrogenic condition. 
2. In vitro methods to model neuron-autonomous mechanisms for PIPN
Several in vitro models, using cultures of primary sensory neurons or neuron-like cell 
lines have been utilized to identify the mechanisms by which paclitaxel alters neuronal 
function and structure. While these in vitro systems are limited in recapitulating the 
interactions of neurons within their in vivo microenvironment, they do allow for direct 
manipulation of protein expression and function via pharmacological and genetic tools 
to interrogate intracellular signaling pathways altered by paclitaxel within the neurons. 
Paclitaxel-induced changes in neuronal sensitivity and excitability have been assessed 
using assays for neurotransmitter release, changes in intracellular calcium levels, and 
electrophysiological techniques. In primary cultures derived from rodent dorsal root 
ganglion neurons, exposure of the cultures to paclitaxel causes time- and concentration-
dependent alterations in the basal and stimulated release of two neuropeptides, 
calcitonin-gene related peptide (CGRP) and substance P (SP). Acute exposure of 
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neuronal cultures to paclitaxel (10nM - 10μM for 10-30 minutes) directly stimulates the 
release of CGRP and SP in a manner dependent on the activation of protein kinase C 
(PKC) (He and Wang, 2015; Miyano et al., 2009). A possible mechanism underlying the 
activation of PKC and neuropeptide release is a transient increase in intracellular 
calcium, an effect observed after acute treatment of both cultured sensory neurons and 
neuroblastoma cells with paclitaxel (Boehmerle et al., 2006; Miyano et al., 2009). 
Putative mechanisms for paclitaxel to acutely enhance intracellular calcium dynamics 
and neuropeptide release include direct activation of the TLR4 by paclitaxel (Li et al., 
2015) and an indirect activation of intracellular calcium release by paclitaxel binding to 
the neuronal calcium sensor-1 (Boehmerle et al., 2006). In contrast to the acute effects 
of paclitaxel, chronic exposure of cultures to paclitaxel (300nM - 1μM, for ≥ 3 days) 
diminishes the release of CGRP stimulated by TRPV1 or TRPA1 agonists (Pittman et 
al., 2014), which occurs concurrent with a diminution in stimulated calcium release from 
intracellular stores (Boehmerle et al., 2007). Proposed mechanisms by which extended 
exposure of neuronal cultures to paclitaxel leads to desensitization of peptide release 
include disruption of axonal transport and subsequent impairment of the movement of 
organelles and/or calcium dysregulation (Boehmerle et al., 2007; Shemesh and Spira, 
2010; Theiss and Meller, 2000), and the loss of PKC activation (Darby et al., 2017).  
Because mechanisms for paclitaxel-induced changes in neuronal sensitivity may differ 
between rodents and humans, research on human primary neurons and neuron-like 
cells induced from human pluripotent stem cells has surged in recent years. Some 
mechanisms for paclitaxel-induced changes identified in rodents have been validated in 
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human neurons, such as a role for paclitaxel to enhance sensitivity of the TRPV1 
through activation of TLR4 (Li et al., 2015); however, fundamental differences between 
human and rodent DRGs also have been identified. Ru Rong Ji’s laboratory has found 
differential sodium channel expression in human and mouse DRG: human DRG 
predominantly express Nav1.7, whereas mouse DRG predominantly express Nav1.8. 
Furthermore, exposure of paclitaxel to cultures derived from human DRG neurons elicits 
an increase in the expression of Nav1.7, but not that of Nav1.8 (Chang et al., 2018). 
Another approach to studying the mechanisms of paclitaxel-induced neurotoxicity in 
cells derived from humans has been to reprogram fibroblasts or embryonic stem cells 
into sensory neuron-like cells, called induced pluripotent stem cells (IPSCs) (Chambers 
et al., 2012; Wainger et al., 2015). If these IPSC neurons closely recapitulate the gene 
expression and cellular functions of sensory neurons, they may provide human-derived 
cells suitable for in vitro mechanistic studies. A distinct advantage of using patient-
derived precursor cells is to recapitulate genotype differences between patient 
populations in vitro, potentially allowing for a correlation between patient-specific 
genotypes with peripheral neuron sensitivity and/or response to injury. To date, the 
studies using IPSC neurons are mostly limited to using cellular morphology as an 
endpoint of neurotoxicity. However, one study examined the effects of paclitaxel on the 
mean firing rate of the IPSC neurons and observed a slight decrease in the firing rate of 
cells following a 48-hour exposure in the absence of any paclitaxel-induced cell death 
(Wing et al., 2017).  
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Patients treated with paclitaxel have a decrease in the density of nerve fibers that 
innervate the epidermis of the hands and feet (Boyette-Davis et al., 2013), and it is likely 
that this “dying back” or retraction of nerve endings underlies some of the symptoms of 
PIPN. A similar length-dependent decrease in intraepidermal innervation is apparent in 
rodents treated with paclitaxel (Boyette-Davis et al., 2011; Jin et al., 2008; Ko et al., 
2014; Siau et al., 2006). The effects of paclitaxel on sensory neuron morphology have 
been examined in DRG explants and dissociated neuronal cultures derived from both 
embryonic and adult rodents and, dependent upon the timing of drug administration to 
the cultures, paclitaxel can either inhibit outgrowth or promote degeneration of existing 
neurites (Gracias et al., 2011; Malgrange et al., 1994; Melli et al., 2006; Pittman et al., 
2016; Yang et al., 2009b). Studies from Ahmet Hoke’s laboratory used a 
compartmentalized microfluidic culture platform to determine whether paclitaxel acts on 
discrete regions of embryonic neurons to elicit changes in the cellular morphology. 
Paclitaxel exposure to the axonal compartment caused a reduction in neurite length; 
however, no changes in neurite length were observed when paclitaxel was applied to 
the soma (Yang et al., 2009a). These studies suggest that the primary site of paclitaxel 
uptake or site of action is along the axons and at the peripheral terminals of sensory 
neurons. Not surprisingly, some of the identified mechanisms by which paclitaxel alters 
cell morphology are similar to those which underlie functional changes in vitro and in 
vivo, including activation of the TLR4 (Ustinova et al., 2013), modulation of calcium 
dynamics (Pease-Raissi et al., 2017), and the production of ROS/RNS (Duggett et al., 
2016; Janes et al., 2013; Melli et al., 2008).  
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In an elegant series of experiments, investigators demonstrated that paclitaxel’s effects 
on microtubule axonal transport decrease the local translation of a Bcl2 family member, 
bclw, in cultures of embryonic sensory neurons. Loss of axonal bclw expression 
dysregulates calcium flux at the endoplasmic reticulum and can lead to activation of 
calcium-dependent calpains that subsequently induce axonal degeneration (Pease-
Raissi et al., 2017). Based upon some early in vivo work, whereby NGF administration 
alleviated the neurotoxic effects of paclitaxel administration to rodents (Apfel et al., 
1991), investigators endeavored to overcome the degenerative effects of 
chemotherapeutics by increasing growth factors in the in vitro culture media (Chen et 
al., 2017; Konings et al., 1994; Malgrange et al., 1994; Pittman et al., 2016). Although a 
protective effect of NGF was observed in embryonic neuronal explants treated with 
paclitaxel (Konings et al., 1994), these findings were not replicated in dissociated 
neurons derived from adult rats (Pittman et al., 2016), thus there might be a contribution 
of development in the protective effects of NGF on neuronal morphology. Other 
neuroprotective agents that have been found to inhibit or counteract the morphological 
changes of neurons induced by paclitaxel or docetaxel include insulin-like growth factor-
1 (Chen et al., 2017), minoxidil (Chen et al., 2017), erythropoietin (Maggioni et al., 2010; 
Melli et al., 2006), and pirenzepine (Calcutt et al., 2017). Interestingly, one study 
combined a functional output to the morphological effects of paclitaxel in vitro. In this 
work, paclitaxel-induced changes in the release of CGRP from adult sensory neurons 
was inhibited by the addition of nerve growth factor to the culture media; however, this 
growth factor addition did not protect against the neurodegenerative effects of paclitaxel 
in decreasing neurite length in the same cultures (Pittman et al., 2016), suggesting that 
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the mechanisms for neuronal sensitivity and neurite growth could be independent. 
Further studies are warranted to determine whether these growth factors abrogate the 
effects of paclitaxel or whether they mask the symptoms because of their growth-
promoting effects. To assess the effects of paclitaxel on human cells, IPSC neurons 
have been exposed to paclitaxel and total neurite outgrowth has been shown to 
decrease with increasing concentrations of paclitaxel. As in rodent models, studies are 
ongoing to test the ability of putative neuroprotective drugs to reverse the degenerative 
effects of paclitaxel on neurite outgrowth (Wing et al., 2017). In summary, neuronal 
cultures provide a reduced system to study the effects of paclitaxel on neuronal 
signaling and provide clear endpoints to assess neuroprotection by putative therapies. 
Using these systems, several neuron-autonomous mechanisms by which paclitaxel 
alters neuronal function and morphology have been identified, providing novel targets 
for pharmacological intervention.  
3. In vivo pathophysiology of taxanes
Several animal studies explored the mechanisms involved in paclitaxel-induced 
peripheral neuropathy (PIPN) in vivo. Some non-mammalian models have also been 
used to understand the mechanisms behind CIPN, such as Zebrafish or Drosophila 
models, and these are described in detail in another review within this Special Issue. 
We will therefore focus our review on rodent studies. Paclitaxel is typically administered 
to mice and rats through intravenous or intraperitoneal injection. The pathophysiological 
processes induced by paclitaxel include inflammation, oxidative stress, loss of primarily 
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epidermal nerve fibers, and alterations of mitochondrial function and excitability of 
peripheral neurons. Various cell types in the peripheral and central nervous system 
have been shown to be affected by paclitaxel treatment in these models, including 
dorsal root ganglion neurons, Schwann cells, satellite glial cells, microglia, epidermis 
and spinal astrocytes. Different mechanisms leading to paclitaxel neurotoxicity in rodent 
models are summarized below: 
3.1 Peripheral neurons 
It is well established that neuropathic pain induced by paclitaxel treatment is 
accompanied by damage of small fiber sensory axons. Many publications report the 
degeneration of fine intra-epidermal nociceptive fibers, as well as axonal demyelination 
due to the loss of contact between axolemma and Schwann cells, and also a loss of 
Meissner’s corpuscles, the sensory end-organ for one mechanosensitive neuron 
subtypes (Beh et al., 2019; Bennett et al., 2011; Boehmerle et al., 2014; Li et al., 2014; 
Pevida et al., 2013; Wozniak et al., 2018). Nociceptive symptoms observed in animals 
reflect alterations of electrophysiological parameters as well as the degeneration of 
nerve endings (Boehmerle et al., 2014; Boyette-Davis et al., 2011). Recently, factors, 
such as Notch1, phosphorylated Janus kinase 2 (p-JAK2), phosphorylated signal 
transducer and activator of transcription 3 (p-STAT3) have been implicated in 
neuropathic pain induced by paclitaxel treatment (Al-Massri et al., 2018, 2019). 
Paclitaxel alters the electrophysiological properties of peripheral neurons in vivo, and 
the effect is dependent upon the modified expression of diverse receptors and voltage-
gated ion channels within dorsal root ganglion neurons, including increased expression 
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of the calcium channels, Cav3.2, Cav2.3, Cav2.2, a decreased expression of the 
potassium channels, K2P and Kv7, and the upregulation of sodium channel Nav1.7, all 
of which results in a gain-of-function (Li et al., 2019; Li et al., 2018; Li et al., 2017; 
Okubo et al., 2011; Shan et al., 2019; Zhang and Dougherty, 2014). Other receptors 
involved in paclitaxel-induced neuropathic pain in rats include glutamatergic receptors. 
Paclitaxel induces a tonic activation of presynaptic NMDA receptors, and increases the 
expression of the voltage-gated calcium channel subunit, α2δ-1, and the NMDA 
receptor subunits, GluN1, GluN2A, and GluN2B (Chen et al., 2019).   
As paclitaxel directly targets microtubules and prevents depolymerization, it is not 
surprising that microtubule dysfunction is prevalent in axons following treatment with 
paclitaxel (Flatters and Bennett, 2006; Xiao et al., 2011; Zheng et al., 2011). It is 
generally accepted from various in vitro and in vivo studies that paclitaxel impedes fast 
axonal transport along microtubule tracks (Bobylev et al., 2015; Malacrida et al., 2019; 
Shemesh and Spira, 2010). While paclitaxel treatment does not directly lead to damage 
of mitochondrial DNA in neurons (Boyette-Davis et al., 2018), swollen and vacuolated 
mitochondria in myelinated and unmyelinated sensory nerve fibers have been observed 
(Flatters and Bennett, 2006), as well as changes in mitochondrial membrane potential 
and subsequent calcium release (Mironov et al., 2005; Yilmaz and Gold, 2016; Yilmaz 
et al., 2017). Mitochondrial damage induced by paclitaxel further leads to the formation 
of reactive oxygen species, resulting in intra-axonal oxidative stress, as indicated by 
numerous studies (Miao et al., 2018; Singh et al., 2019; Sun et al., 2019; Zhao et al., 
2019). For instance, it was found that lipid peroxidation was augmented and glutathione 
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levels increased, whereas expression of the antioxidant enzyme, superoxide dismutase, 
was decreased in the sciatic nerve and DRG neurons following paclitaxel treatment 
(Miao et al., 2018; Sun et al., 2019). Treatment of mice with paclitaxel resulted in 
impaired Nrf2-antioxidant response element (Nrf2-ARE) function and decreased Nrf2-
responsive gene (HO-1, γ-GCLC, and NQO1) expression, associated with neuropathic 
pain (Zhao et al., 2019).  Whether the increase in oxidative stress contributes to 
degeneration of nerve endings has, however, not been directly tested in rodents. 
However, a recent study demonstrated in zebrafish that axons do not show increased 
oxidative stress upon paclitaxel treatment despite that axonal mitochondria are 
vacuolated (Cirrincione et al., 2019). Intriguingly, rather than a role for intrinsic effects of 
paclitaxel in axon degeneration, epidermally expressed MMP-13 appears to play a role 
in neuropathy of rats and mice injected with paclitaxel. MMP-13 was previously shown 
to mediate axon degeneration in the zebrafish model since it is upregulated upon 
paclitaxel treatment and its pharmacological inhibition prevented axon degeneration 
(Lisse et al., 2016); yet vacuolation of axonal mitochondria still occurs in inhibitor treated 
zebrafish. Pharmacological inhibition of MMP-13 either by intraperitoneal injection or 
upon topical administration to the paw pad of rats also prevented paclitaxel-induced 
neuropathy (mechanical and cold hypersensitivity), suggesting that MMP-13 dependent 
mechanisms are conserved. Taken together, evidence points to a multitude of 
mechanisms leading to paclitaxel-induced axon damage, including inflammation, 
microtubule aggregation and transport defects, and mitochondrial changes. Whether 
these phenotypes are underlying axon degeneration remains to be tested in vivo. New 
molecular players originally identified in zebrafish and validated in mammals, such as 
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MMP-13, could serve as new targets in the treatment of paclitaxel-induced peripheral 
neuropathy. 
3.2 Immune cells and glia 
Paclitaxel treatment induces inflammation, with numerous pro-inflammatory chemokines 
released from either dorsal root ganglion neurons or associated cells. Receptor-
mediated signaling by these chemokines can cause neuropathic pain. For example, the 
chemokine CXCL8 (otherwise known as IL-8) and its receptors CXCR1/2 are 
upregulated in rat dorsal root ganglion neurons. Importantly inhibition of 
CXCL8/CXCR1/2 signaling reduced paclitaxel-induced nociception and alleviated 
mechanical and cold hypersensitivity in a rat model (Brandolini et al., 2017). More 
recently, it was shown that upregulation of another chemokine, CXCL1, and its receptor 
CXCR2 and subsequent activation of PI3K contributes to the development and 
maintenance of paclitaxel-induced mechanical hypersensitivity in mice (Manjavachi et 
al., 2019). Paclitaxel treatment of mice can cause accumulation of macrophages in the 
sciatic nerve, and upregulation of the chemokine receptor, CXCR4, and RAGE 
(Receptor for Advanced Glycation Endproducts) in dorsal root ganglia. Intriguingly, 
antagonists for CXCR4 and RAGE can prevent paclitaxel-induced allodynia (Sekiguchi 
et al., 2018). Another chemokine, MCP-1/CCL-2 (Monocyte Chemoattractant Protein 1) 
and its cognate receptor CCR2 may also play a role in paclitaxel-induced inflammation 
and macrophage migration, as increased MCP-1 expression was observed in small 
nociceptive dorsal root ganglion neurons and in spinal astrocytes in rats treated with 
paclitaxel (Zhang et al., 2013). This chemokine may stimulate CCR2 which is expressed 
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in large and medium-sized myelinated neurons. Direct addition of MCP-1 to dorsal root 
ganglion neurons led to calcium spikes selectively in CCR2-positive medium-sized 
neurons, and injection of anti-MCP-1 antibodies and CCR2 antisense oligonucleotides 
reduced intra-epidermal nerve fiber loss and mechanical hypersensitivity (Zhang et al., 
2016). Similarly, previous studies showed that paclitaxel induces an inflammatory 
response in dorsal root ganglion neurons by activating the Toll-like receptor 4 (TLR4) 
pathway and increasing MCP-1 expression (Byrd-Leifer et al., 2001) (Li et al., 2014). 
Taken together, chemokine signaling plays a critical part in the crosstalk among 
different dorsal root ganglion neuron subpopulations and so contributes to neuropathic 
pain and allodynia. Cytokine-dependent nuclear translocation of nuclear factor-B 
(NFB), which regulates nerve growth factor, promotes paclitaxel-induced mechanical, 
thermal and cold hypersensitivity in outbred ICR mice (Meng et al., 2019). In this study, 
nuclear NF-B translocation and peripheral nerve injury could be blocked by inhibiting 
the activation of p38 phosphorylation via duloxetine. 
Recently a mechanistic link between complement, a key component of the innate 
immune system, and paclitaxel-induced peripheral neuropathy has been found (Xu et 
al., 2018). Using CRISPR/Cas9 in rats, a major component of this system, C3, was 
knocked out to study its involvement in paclitaxel-induced neuropathy. Rats lacking C3 
showed improved sensitivity to touch and reduced loss of intradermal nerve fibers. 
Furthermore in vitro studies using the neuronal cell line PC12 revealed that paclitaxel 
treatment enhances C3 activation and this contributes to cytotoxicity.  
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Increasing evidence indicates that non-neuronal cells, including microglia and 
astrocytes of the CNS, are also involved in the initiation and resolution of pain. The role 
of microglia in paclitaxel-induced peripheral neuropathy has therefore been the subject 
to a few recent studies. It was shown that paclitaxel treatment induces microglia 
dysregulation in the dorsal horn of the spinal cord and increases the expression of 
cannabinoid type 2 receptor (CB2), and of the chemokines, CCL2 and interleukin (IL-6, 
IL-4 and IL-10) (Ha et al., 2019; Pevida et al., 2013; Wu et al., 2019). More recently, 
there has been a growing interest in cannabinoid receptors in the treatment of 
neuropathic pain. For example, by modulating microglia these receptors can have 
analgesic properties and reduce pain associated with paclitaxel-induced neuropathy 
(Burgos et al., 2012; Wu et al., 2019).  Paclitaxel has further been shown to induce 
neuropathic pain by activation of spinal astrocytes, which causes the secretion of pro-
inflammatory cytokines, i.e. tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and 
IL-6 (Ba et al., 2018; Burgos et al., 2012).   
Other glia cells, such as satellite glial cells that support and surround DRG neuronal cell 
bodies, have been shown to play an additional role in paclitaxel-induced peripheral 
neuropathy. For example, paclitaxel treatment leads to increased gap junction coupling 
among satellite glial cells, which may contribute to pain sensation (Warwick and Hanani, 
2013). It has been suggested that activation of TLR4 in satellite glial cells stimulates the 
release of TNF-α and subsequent inflammation, TRP channel activation, and pain 
sensation (Boehmerle et al., 2018; Duggett et al., 2016; Materazzi et al., 2012; Wu et 
al., 2015). Interestingly, TRPA1 and TRPV4 have also been implicated in paclitaxel-
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induced cold hypersensitivity (Alessandri-Haber et al., 2004) Satellite glial cells were 
further shown to upregulate angiotensin II type 1 receptor (AT1R) following paclitaxel 
treatment, which increases the expression of inflammatory cytokines, such as IL-1β and 
TNF-α in the nearby dorsal root ganglion neurons (Kim et al., 2019).  
3.3 Pathogenesis of other taxanes leading to peripheral neuropathy 
 Along with paclitaxel, also docetaxel and cabazitaxel belong to the family of taxanes 
that are used in oncology and which can cause peripheral neuropathy, although not as 
severe as the effects induced by paclitaxel treatment. However, few studies explored 
their mechanisms in this condition. Docetaxel binds to tubulin with greater affinity than 
paclitaxel and causes cell cycle arrest in the S rather than G2-M phase junction as is 
the case for paclitaxel (Dorr, 1997). Nonetheless, paclitaxel is more commonly 
associated with the development of CIPN in cancer patients (Chon et al., 2009; Hilkens 
and ven den Bent, 1997). In animal studies, docetaxel is typically administered to mice 
and rats through intravenous or intraperitoneal injection. However, few studies have 
described docetaxel-induced peripheral neuropathies. A decrease in nerve conduction 
velocity was observed for intravenous injection of docetaxel at doses between 5 and 
12.5 mg/kg in rats (Persohn et al., 2005). Nevertheless, no significant changes in sciatic 
nerve morphology (number of fibers and demyelinization) have been reported (Persohn 
et al., 2005). Another study showed a decrease in nerve conduction velocity, 
intraepidermal fiber numbers and myelin protein expression in a docetaxel rat model 
(10mg/kg, i.v., 4 weeks) (Roglio et al., 2009). More recently, there have been reports of 
the involvement of TRPA1 receptors (through upward regulation) in the development of 
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mechanical allodynia induced by docetaxel (Huang et al., 2017). Cabazitaxel is a 
dimethyl derivative of docetaxel with equivalent efficacy to docetaxel for stabilizing 
microtubules in vitro. Clinical studies suggest that the incidence and severity of 
peripheral neuropathy may be lower with cabazitaxel compared with other taxanes (de 
Bono et al., 2010). However, to our knowledge, no animal studies explored the 
mechanisms involved in peripheral neuropathies and neuropathic pain induced by 
cabazitaxel.  
4. Human genetic studies provide insight into clinical paclitaxel neurotoxicity
Human genetic studies have provided pathomechanistic insight into taxane-induced 
peripheral neuropathy. The genetic study design takes advantage of an important 
clinical fact: for a given taxane exposure, neuropathy can have dramatically variable 
severity or may not occur at all. By comparing genotypes in patients with varying CIPN 
phenotypes, these studies have uncovered specific genes and pathways that may 
underlie CIPN susceptibility. There are two broad approaches that are employed in 
these genetic studies: targeted or unbiased. In the targeted approach, specific genes 
that are hypothesized to contribute to CIPN susceptibility are investigated (i.e. 
neuropathy or metabolism genes), whereas in the unbiased studies, genome wide 
associations are investigated that may uncover unexpected pathways. 
A review of available human genetic studies of taxane-induced neuropathy susceptibility 
on PubMed revealed 30 studies dating back to 2006, which includes both targeted 
(Abraham et al., 2014; Apellaniz-Ruiz et al., 2015; Apellaniz-Ruiz et al., 2017; Beutler et 
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al., 2014; Boora et al., 2016; Boora et al., 2015; de Graan et al., 2013; Dou et al., 2017; 
Eckhoff et al., 2015; Hertz et al., 2014; Hertz et al., 2013; Kulkarni et al., 2015; Leandro-
Garcia et al., 2012; Lee et al., 2015a; Leskela et al., 2011; McWhinney-Glass et al., 
2013; Mir et al., 2009; Park et al., 2017; Park et al., 2014; Sissung et al., 2006; 
Sucheston et al., 2011; Tanabe et al., 2017) and unbiased (Baldwin et al., 2012; 
Bergmann et al., 2013; Hertz et al., 2016; Leandro-Garcia et al., 2013; Schneider et al., 
2016; Schneider et al., 2015; Sucheston-Campbell et al., 2018; Wheeler et al., 2013) 
approaches.  Polymorphisms and mutations in genes that have been associated with 
altered risk of taxane neuropathy include genes in structural and cytoskeletal pathways, 
such as LIMK2 (Dou et al., 2017; Leandro-Garcia et al., 2013), MAPT (Park et al., 
2017), SBF2 (Schneider et al., 2016), PRX (Beutler et al., 2014), TUBB2A (Abraham et 
al., 2014; Leandro-Garcia et al., 2012), TECTA (Bergmann et al., 2013), FGD4 (Baldwin 
et al., 2012), in neural developmental pathways, including GSK3B (Park et al., 2017; 
Park et al., 2014), EPHA4-6 (Apellaniz-Ruiz et al., 2017; Boora et al., 2016; Leandro-
Garcia et al., 2013), BDNF (Azoulay et al., 2015), ARGHEF10 (Beutler et al., 2014; 
Boora et al., 2015), GPR177 (Schneider et al., 2015), SOX10 (McWhinney-Glass et al., 
2013), in cell damage and apoptosis, including BCL2 (McWhinney-Glass et al., 2013), 
RWDD3 (Bergmann et al., 2013), FANCD2 (Sucheston et al., 2011), and in drug 
metabolism, including ABCB1 (Abraham et al., 2014; Boora et al., 2016; Sissung et al., 
2006; Tanabe et al., 2017), CYP genes (Apellaniz-Ruiz et al., 2015; de Graan et al., 
2013; Hertz et al., 2014; Hertz et al., 2013; Lee et al., 2015b; Leskela et al., 2011), 
GSTP1 (Eckhoff et al., 2015; Mir et al., 2009), in addition to several genes that when 
mutated can cause Charcot-Marie Tooth Disease and other neurodegenerative 
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diseases (Baldwin et al., 2012; Beutler et al., 2014; Boora et al., 2015; Hertz et al., 
2016; Schneider et al., 2016). While these studies have provided mechanistic insights to 
genes and pathways that might influence taxane-induced peripheral neuropathy, many 
of these genetic association studies have been fraught with methodological problems 
and challenges with reproducibility. Varied methods of genetic analysis, underpowered 
studies, lack of validated cohorts, neuropathy phenotyping, and concomitant neurotoxic 
chemotherapies (often platinum-based compounds) have unfortunately prevented wide 
applicability of these studies (Argyriou et al., 2017; Cavaletti et al., 2011).  A recent 
review suggested that ABCB1, TUBB2A, GPR177, and EPHA4-6 were the genes that 
had the strongest data supporting their role in taxane-induced neuropathy susceptibility 
and should be validated further (Argyriou et al., 2017). 
Attempts at prevention of taxane-induced neuropathy or its treatment have been 
disappointing in human clinical trials. The only clear success in a large randomized 
clinical trial was the demonstration that duloxetine provides a modest improvement of 
pain in patients with established CIPN (Smith et al., 2013).  All other studies were either 
negative or showed benefits in small cohorts that have not been reproduced (Majithia et 
al., 2016). Failed prevention trials have focused on diffuse neuroprotection and have 
employed agents that are cytoprotective, antioxidants and improve mitochondria 
function (Amifostine, glutathione, vitamin E, acetyl-L-carnitine). It is hoped that more 
targeted prevention strategies that focus on unique aspects of CIPN (drug transporters, 
axonal degeneration, neuroinflammation) will be able to prevent CIPN while still 
maintaining taxanes’ tumor-killing properties. 
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In all the human CIPN studies described above, it is critical that researchers are able to 
accurately determine the presence of a given patient’s CIPN and its severity.  In the 
complicated clinical setting of a patient with cancer, this is less straightforward than it 
may initially seem. There has been intensive research into the methodology of 
quantitating CIPN in patients, which broadly can be divided into clinician-reported 
outcomes (ClinROs) and patient reported outcomes (PROs).  ClinROs may include very 
blunt instruments such as the Common Terminology Criteria for Adverse Events 
(CTCAE) or more sensitive assessments such as, quantitative neurological 
examinations, neurophysiology, or nerve pathology (Argyriou et al., 2019).  PROs in 
CIPN have become more widely used and are typically questionnaires related to 
symptoms (sensory, motor and autonomic) (Griffith et al., 2010) or functionality (e.g. 
activity of daily living) (Binda et al., 2015).  Many of the above cited studies used poorly 
sensitive or specific CIPN tools such as the CTCAE, which raises concerns about the 
reliability of their findings.  Fortunately, the more sensitive CIPN measurements, often a 
combination of ClinROs and PROs, are now routinely being incorporated into human 
studies of CIPN (Gewandter et al., 2018). 
5. Conclusions
Of the patients given paclitaxel for cancer treatment, about 60-70% suffer from 
paclitaxel-induced peripheral neuropathy (Seretny et al., 2014). Paclitaxel-induced 
peripheral neuropathy, among other chemotherapy-induced peripheral neuropathies, is 
a major reason for early termination of chemotherapy. Although many groups have 
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begun to uncover mechanisms by which paclitaxel causes neuropathy, there are 
currently no effective clinical treatments available for this condition. Several questions 
are being addressed, including (i) What are the direct effects of paclitaxel on sensory 
axons? (ii) What type of damage causes specific symptoms? and (iii) Are the neurons or 
other cell types connect to neurons the primary targets of paclitaxel leading to 
neuropathy? In addition, it will be important to address whether alternative mechanisms, 
besides microtubule damage, which is the primary effect in cancer treatment, could 
cause axon degeneration. Addressing these questions is likely to enable the 
development of new treatments.  
Microtubule stabilization has been analyzed as a potential cause of axonal 
degeneration, but most of the knowledge in this respect has been derived from in vitro 
analyses. An important observation in vitro and in vivo is that mitochondrial damage 
associated with oxidative stress also contributes to nerve damage, and given findings in 
the cancer field, which show that mitochondria can be directly targeted by paclitaxel and 
damaged (André et al., 2002; Kidd et al., 2002; Varbiro et al., 2001), it is possible that 
mitochondrial damage is a primary cause of axon degeneration through the formation of 
reactive oxygen species. Intriguing and consistent with this idea are findings that in 
some human trials, antioxidants such as Amifostine, acetyl-L-carnitine, -carotene and 
-tocopherol are beneficial to patients. Nevertheless, clinical trials with these agents
have also revealed a great variability among between individual patients, which has 
prevented their widespread clinical use despite FDA approval (Block and Gyllenhaal, 
2005; Maestri et al., 2005). The difficulty in using antioxidant therapies in addition to 
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cancer treatment is that interference with reactive oxygen species may exert 
widespread toxicities. For instance, cells depend on low-level reactive oxygen species 
whereas their overproduction in diseases like cancer, or due to chemotherapy 
treatment, causes cellular damage. Thus, finding the proper balance of antioxidants 
during treatment will be important but is inherently difficult. Intravenous injections of the 
antioxidant and anti-inflammatory agent, Amifostine, for instance, led to a wide variety of 
systemic toxicities like hypotension, nausea, vomiting, and hypocalcemia (Block and 
Gyllenhaal, 2005). On the other hand, many, but not all, of these toxicities were 
eliminated upon subcutaneous administration. This further highlights the complexity of 
oxidation and proper delivery of these agents into inherently different tissues and/ or cell 
types. Targeted approaches, such as those that manipulate the function of downstream 
or upstream factors of reactive oxygen species will likely be much more controllable 
since these approaches target one or few specific pathways. Efforts in the private sector 
have been under way to target, for instance, mitochondria damage induced by paclitaxel 
treatment to reduce the formation of reactive oxygen species.  
Given a relatively broad understanding of potential mechanisms implicated in paclitaxel-
induced peripheral neuropathy, the mechanisms identified thus far need to be carefully 
dissected in pre-clinical models in order to determine whether any of those might be 
useful for the development of treatments. Future efforts need to be directed at validating 
this mechanistic data in humans. One approach could be, for example, to compare data 
across species and with data in humans, such as patient databases. Conservation of 
mechanisms across multiple species including non-mammalian and mammalian 
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vertebrates or invertebrates has a higher chance to also be conserved in humans. Prior 
to clinical trials, some of the findings could be further validated using patient-derived 
induced pluripotent stem cells, for example. Generating new data sets from patient 
samples derived either from tissue storage resources or clinical trials could also be 
useful. Various efforts are currently under way, such as within the Toxic Neuropathy 
Consortium, to collect patient data across the globe for comparative purposes, which 
will be available to clinicians and scientists.  
Additional efforts should be made to develop two classes of treatments, one class 
comprising preventative therapies, and those that can reverse the symptoms in those 
patients already suffering from the condition. Ideally one therapy shows efficacy toward 
both. These therapies could either target pathways inducing axon de- and regeneration 
or mitigate or prevent pain symptoms without opioid-based drugs. To date, most efforts 
concentrate on preventing painful neuropathies, which could be related to the increased 
efforts related to pain research. Some studies using non-mammalian in vivo models 
have in contrast been quite successful in their identification of new candidate targeting 
axon de- and regeneration pathways, which are also discussed in this Special issue.   
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Fig. 1. Mechanisms of paclitaxel pathogenesis leading to axon degeneration and 
painful neuropathy based on mammalian studies. Isolated rodent DRG neurons and 
patient-derived induced pluripotent stem cells have revealed acute and chronic changes 
in calcium signaling in vitro. In vivo studies using rodent models have shown various 
effects directly in sensory neurons and indirectly in skin cells, immune cells and glia. 
Genetic studies using patient data identified polymorphisms and mutations in various 
pathways associated with increased risk for paclitaxel-induced peripheral neuropathy 
(PIPN). Clinical trials for antioxidants have so far failed to prevent or reverse paclitaxel- 
neurotoxicity.  
Highlights 
 Inflammation, ion channel function and perturbed calcium homeostasis contribute
to paclitaxel-induced neuropathic pain
 Reactive oxygen species formation and altered microtubule function are common
in animal models of paclitaxel-induced peripheral neuropathy
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 Genetic studies in patients with paclitaxel-induced peripheral neuropathy have
revealed genes that are also altered in animal models and could represent new
targets in the treatment of this condition
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